Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced that the company has received additional orders for the CADScor«System in Louisiana. The orders are a result of a previously announced collaboration with
Bio-Rhythms Inc, targeting an area with the highest prevalence of heart disease in the United States. Louisiana is in the top-5 of US states based on heart disease death rates, due to a high frequency of obesity, diabetes, and kidney disease, all of which are risk factors for heart disease. The number of patients and the need for rapid assessment and exclusion of heart disease is therefore high. The Acarix CADScor«System is an acoustic and AI-based solution to rapidly and non- invasively evaluate patients with chest pains in 10 minutes. Its CPT-III code became effective in July 2022, and clinics are now receiving reimbursement payments from US insurance companies.